Skip to main content
Print Save

Menactra Disease Interactions

There are 3 disease interactions with Menactra (meningococcal conjugate vaccine).

Major

Vaccines (applies to Menactra) IM injection

Major Potential Hazard, Moderate plausibility. Applicable conditions: Thrombocytopenia, Thrombocytopathy, Coagulation Defect

In patients with thrombocytopenia or coagulation disorders, intramuscular injections may produce bleeding and hematomas. Patients with a platelet count less than 50,000/mm3 are at an increased risk. Caution is advised if the vaccine (e.g., plague vaccine, hepatitis A and B vaccines, and aluminum-adsorbed DTaP, DTP, DT, or Td) must be administered intramuscularly. The risk of bleeding may be minimized by vaccination immediately after the administration of replacement factor, use of a 23-gauge (or smaller) needle, and immediate application of direct pressure to the vaccination site for at least 2 minutes.

References

  1. "Product Information. Plague Vaccine (plague vaccine)." Greer Laboratories Inc (2001):
  2. American Academy of Pediatrics. Committee on Infectious Diseases; Peter G, ed. "Red BooK: Report of the Committee on Infectious Diseases." Grove Village, IL: American Academy of Pediatrics (1997):
  3. "Product Information. Cholera Vaccine (cholera vaccine)." Wyeth-Ayerst Laboratories
  4. "Product Information. Havrix (hepatitis A adult vaccine)." SmithKline Beecham
  5. "Product Information. Engerix-B (hepatitis B adult vaccine)." Apothecon Inc (2022):
  6. "Product Information. Menactra (meningococcal conjugate vaccine)." sanofi pasteur (2005):
  7. "Product Information. ActHIB (haemophilus b conjugate (PRP-T) vaccine)." sanofi pasteur (2022):
  8. "Product Information. Imogam Rabies-HT (rabies immune globulin, human)." sanofi pasteur (2010):
  9. "Product Information. Hyperrab S/D (rabies immune globulin, human)." Grifols Therapeutics (2015):
  10. "Product Information. Bexsero (meningococcal group B vaccine)." Novartis Vaccines & Diagnostics Inc (2022):
View all 10 references
Moderate

Meningococcal conjugate vaccine (applies to Menactra) GBS

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Guillain-Barre Syndrome

Persons previously diagnosed with Guillain-Barré syndrome (GBS) may be at increased risk of GBS following receipt of meningococcal conjugate vaccine. The decision to give this vaccine should take into account the potential benefits and risks.

References

  1. "Product Information. Menactra (meningococcal conjugate vaccine)." sanofi pasteur (2005):
Moderate

Vaccines (live attenuated/toxoid) (applies to Menactra) immunocompromised

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Immunodeficiency

The expected antibody responses may not be obtained when live attenuated vaccines and/or toxoids are administered to immunosuppressed persons, including those receiving immunosuppressive therapy. Caution and close monitoring is advised.

References

  1. "Product Information. Menactra (meningococcal conjugate vaccine)." sanofi pasteur (2005):
  2. "Product Information. ActHIB (haemophilus b conjugate (PRP-T) vaccine)." sanofi pasteur (2022):
  3. "Product Information. Bexsero (meningococcal group B vaccine)." Novartis Vaccines & Diagnostics Inc (2022):
  4. "Product Information. Trumenba (meningococcal group B vaccine)." Pfizer U.S. Pharmaceuticals Group (2022):
  5. "Product Information. Hiberix (haemophilus b conjugate (PRP-T) vaccine)." GlaxoSmithKline (2022):
  6. "Product Information. Vaxchora (cholera vaccine, live)." PaxVax (2016):
View all 6 references

Menactra drug interactions

There are 262 drug interactions with Menactra (meningococcal conjugate vaccine).

Report options

Share by QR Code
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer